Systemic lupus erythematosus (SLE) is a systemic and poly-aetiological autoimmune disease characterized by the production of antibodies to autologous double-stranded DNA (dsDNA) which serve as diagnostic and prognostic markers. The defective clearance of apoptotic material, together with neutrophil extracellular traps (NETs), provides abundant chromatin or self-dsDNA to trigger the production of anti-dsDNA antibodies, although the mechanisms remain to be elucidated. In SLE patients, the immune complex (IC) of dsDNA and its autoantibodies trigger the robust type I interferon (IFN-I) production through intracellular DNA sensors, which drives the adaptive immune system to break down self-tolerance. In this review, we will discuss the potential resources of self-dsDNA, the mechanisms of self-dsDNA-mediated inflammation through various DNA sensors and its functions in SLE pathogenesis.
Introduction
The immune system maintains a delicate balance between the immune response against pathogen invasion and immune tolerance to self-antigen, so-called immune homoeostasis. The defective immune response leads to infection and tumour growth, while an overwhelming immune response causes autoimmune diseases. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of antibodies to various nuclear antigens, named anti-nuclear antibodies (ANAs). Among these ANAs, anti-double-stranded DNA (antidsDNA) antibodies serve as diagnostic and prognostic markers and play important roles in the pathogenesis of lupus nephritis (LN), a major cause of morbidity and mortality of SLE [1] . Since the 1970s, the level of ANA or antidsDNA antibody has been accepted in SLE classification criteria by the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) [1] . Recently, significant effort has been taken to understand the function of self-dsDNA in SLE pathogenesis and how it triggers autoimmunity in SLE patients [2, 3] .
There are multiple mechanisms to keep self-dsDNA away from immune recognition; for example, dsDNA is restricted in nucleus and mitochondria in cells and degraded quickly by DNases in cytoplasm and endosomes. A defect in these mechanisms, for instance, inefficient clearance of apoptotic cell debris and neutrophil extracellular traps (NETs), results in the accumulation of self-dsDNA [4, 5] . Self-dsDNA is involved in the initiation and pathogenesis of SLE through different mechanisms. To initiate autoimmune diseases, the presence of dsDNA in sites of immune privilege is required to break the tolerance to autoantigen and to induce autoantibody production. Meanwhile, apoptotic cell-derived self-dsDNA in the germinal centre (GC) of SLE patients may be presented by follicular dendritic cells as antigen to autoreactive B cells, providing the survival signal to prevent those B cells being eliminated [6] . Regarding the pathogenesis of SLE, selfdsDNA, together with autoantibodies, contributes to multiple clinical features of SLE, including immune complex (IC)-mediated tissue damage, inflammatory cytokine production and the interferon (IFN) signature. Of note, selfdsDNA is sensed mainly by plasmacytoid dendritic cells (pDC) through various DNA sensors, leading to robust type I interferon (IFN-I) production [7] . IFN-I has many immune functions, from stimulating differentiation and maturation of dendritic cells to activating T cells and promoting antibody production by B cells, which highlights the critical function of IFN-I in the pathogenesis of autoimmune diseases, especially SLE [7, 8] . In this review, we will summarize the knowledge concerning the mechanisms of self-dsDNA-mediated inflammation through DNA sensors and its functions in SLE pathogenesis, which may lead to the discovery of new therapeutic strategies of SLE.
Cell death and self-dsDNA in SLE
The aetiology of SLE is multi-factorial, including genetic and environmental factors which lead to presentation of autoantigen, production of autoantibody, chronic inflammation and tissue damage [3] . Self-dsDNA is restricted strictly to the nucleus and mitochondria, but could be released from these organelles in the process of cell death [9] . Cell death, including apoptosis, necrosis and NETosis (special cell death of neutrophil through NETs), is the major potential resource of self-dsDNA which activates the immune system and leads finally to autoimmune disease [10] .
Apoptosis is also called programmed cell death, which is crucial to maintain tissue homeostasis in development and ageing. The process of apoptosis typically includes cell shrinkage, cytoskeleton remodelling, chromatin condensation, nuclear fragmentation, plasma membrane blebbing and apoptotic body formation [11] . Normally, apoptotic cells are phagocytosed immediately by phagocytes and degraded within the lysosomes without causing an inflammation and immune response. Indeed, the integrity of the cellular membrane is well maintained, and engulfing phagocytes secrete anti-inflammatory cytokines [11] . However, apoptotic cells which are not cleared quickly and efficiently undergo secondary necrosis, accompanied by rupture of the cell membrane and subsequent release of pathogenic intracellular contents, including self-dsDNA [12] . It is noteworthy that primary necrosis triggered by exogenous factors also leads to the release of intracellular material and contributes to the development of autoimmune diseases [13, 14] . NETosis is a special cell death executed by neutrophils, in which nuclear DNA, histones and granular antimicrobial proteins are extruded from the cells forming NETs [15] . Moreover, other types of cell, such as eosinophils and mast cells, are reported to undergo cell death by a similar mechanism. In this regard, NETosis is not limited to neutrophils, but represents a new class of cell death with extracellular traps release [16] . In the physiological scenario, monocyte-derived macrophages clear NETs efficiently, and this process is facilitated by the extracellular preprocessing of NETs by DNase I and C1q [17] . After being ingested by macrophages, NETs are transported via phagosomes into lysosomes for degradation. The uptake of NETs by macrophages does not induce proinflammatory cytokine secretion, indicating that this process is immunologically silent [17] . A defect in this process will cause the accumulation of autoantigens including dsDNA [18] [19] [20] , although another study has shown a protective role of NETs in SLE [21] . Recently, emerging evidence indicates that self-dsDNA released from cell death plays a crucial role in SLE pathogenesis (Fig. 1) .
Self-dsDNA released by apoptotic cells
Physiologically, clearance of apoptotic cells by phagocytes relies directly and indirectly upon phosphatidylserine (PS) [11] . PS on the surface of apoptotic cells could be recognized by phagocytes via its receptors, such as T cell immunoglobulin (Ig) and mucin domain-containing molecule 4 (Tim4). Meanwhile, PS could interact with phagocytes indirectly through bridging proteins, such as complement C1q, the milk fat globule EGF factor 8 (MFG-E8) or growth arrestspecific 6 (Gas6) [4, 11] . The binding of PS with its receptor induces rearrangement of the actin cytoskeleton and internalization of apoptotic cells [4, 11] . Tim-4-deficient mice show the phenotype of presentation of anti-dsDNA antibodies, and elevated B and T cell activation [22] . A deficiency of C1q or MFG-E8 in the murine model results in remarkable autoimmunity, as indicated by anti-dsDNA autoantibodies and glomerulonephritis [23, 24] . Mice lacking the membrane tyrosine kinase c-mer, a receptor on phagocytes for bridging Gas6 to PS, have impaired clearance of apoptotic cells and develop progressive lupus-like autoimmunity symptoms with antibodies to chromatin and DNA [25] . DNase II is located in the lysosomes of phagocytes, where it degrades DNA from engulfed apoptotic cells. DNase II knock-out mouse is embryonically lethal; however, it could be viable if the IFN receptor I gene is deleted, with chronic polyarthritis resembling human rheumatoid arthritis rather than symptoms of SLE [26] .
Consistent with findings from animal studies, emerging evidence shows that the clearance of apoptotic cells is impaired in SLE patients. Gaipl and colleagues found that CD34 1 CD45 1 haematopoietic stem cells isolated from peripheral blood of SLE patients show reduced differentiation to macrophages when stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) in vitro [27] .
Macrophages from SLE patients cultured in vitro are smaller, with impaired adhesion and decreased phagocytic capacity for autologous apoptotic material [28, 29] . More direct evidence of the involvement of clearance deficiency in the aetiology of SLE comes from lymph node biopsy. Normally, apoptotic cells in lymph nodes are engulfed and degraded by so-called tingible body macrophages (TBMs), which are located in GCs in close proximity to follicular dendritic cells [6] . However, TBMs are smaller in SLE patients. The proportion of macrophages containing ingested material of apoptotic cell is remarkably reduced, suggesting that these cells have a defective capacity to clear apoptotic cells, as the resulting nuclear remnants of apoptotic cells are accumulated in GCs [6] . Abnormally activated or overwhelmed macrophages are also associated with dysregulated T cell functions and autoantibody production, which is found in some SLE patients, suggesting a unique role of macrophage in SLE pathogenesis [30] . Taken together, inefficient clearance of apoptotic cells is one major cause of SLE, the consequence of which is the constitutive presence of autoantigens including DNA.
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Self-dsDNA released through NETs
The clearance of NETs in vivo depends highly upon DNase I, which is the major DNA endonuclease in circulation. DNase I-deficient mice develop the classical symptoms of SLE, such as the presence of ANAs, including anti-dsDNA antibodies, IC in glomeruli and glomerulonephritis [18] . DNase I activity in serum is actually lower in SLE patients than in healthy individuals [18] . IC-containing neutrophil-derived antimicrobial peptides, self-dsDNA and their specific antibodies are found in SLE patients, suggesting that accumulation of self-dsDNA could be because the capability of DNase I has been over-run, which might worsen when DNase I activity is impaired. [18, 31] . Moreover, DNase I specific inhibitors could prevent NETs degradation [31] . Anti-NET antibodies, C1q, anti-microbial peptide LL-37 or high mobility group box 1 protein (HMGB1) binding to NETs could also interrupt NETs degradation mediated by DNase I and contribute to the pathogenesis of SLE [5, 32, 33] . As discussed above, emerging evidence implies that impaired DNase I activity leads to defective degradation of NETs and release of self-dsDNA, which subsequently promotes autoantibody production, inflammation and tissue damage. Additionally, the accumulation of DNA may also be attributed to the enhanced capacity for NETosis in SLE patients. Neutrophils from lupus mice and SLE patients undergo NETosis more easily than those from healthy controls [5, 19, 20] . Neutrophils exposed to ribonucleoprotein immune complexes are liable to undergo NETosis through the induction of mitochondrial reactive oxygen species (ROS) [34] . Moreover, SLE patients have a distinct subset of proinflammatory neutrophils, lowdensity granulocytes (LDGs) [35] , which have an enhanced capacity of forming NETs [20] and synthesizing mitochondrial ROS [34] . Taken together, all these studies provide convincing evidence that NETosis is one of the major sources of self-dsDNA, and a defect in NETs clearance plays an important role in SLE pathogenesis.
Self-dsDNA released by necrosis
Necrosis is considered to be an accidental cell death mechanism, which is triggered usually by external factors such as trauma or infection, resulting in the loss of cell membrane Fig. 1 . Self-dsDNA involved in the pathogenesis of systemic lupus erythematosus (SLE). In SLE patients, the clearance of apoptosis, necrosis and neutrophil extracellular traps (NETs) is defective which is the major resource of self-dsDNA to induce autoantibody production with unrevealed mechanism. Anti-dsDNA antibodies are produced by autoreactive B cells with the help of autoreactive T cells. Immune complex of dsDNA and its autoantibody triggers the robust type I interferon (IFN-I) production through various intercellular DNA sensors in phagocytes and plasmacytoid dendritic cells (pDC). IFN-I is the driving force in SLE pathogenesis by participating in inflammatory reactions, tissue damage, DC maturation and activation of autoreactive T and B cells. integrity and an uncontrolled release of intracellular material, including self-dsDNA, into the extracellular space [15] . Even the aetiological role of necrosis in SLE pathogenesis is controversial; it is accepted that trauma and infection-associated necrosis aggravates the pre-existing SLE [13, 14, 36] . In addition, extremely harsh physical conditions such as anoxia or high concentrations of prooxidants could also cause necrosis in vivo, which is a common condition during the pathological process of SLE. Under these conditions, necrosis could be recognized as one part of the vicious loop of the disease [37] ; however, its function in the aetiology of SLE needs to be studied further.
Role of dsDNA in antibody production
Pathogen-derived exogenous DNA is immunogenic, but the immunogenicity of self-dsDNA remains to be elucidated [9] . Bacterial dsDNA with unmethylated cytosinephosphate-guanine (CpG) motifs induces anti-dsDNA antibodies in both wild-type and lupus mice. Whereas wild-type mice produce antibodies specific for bacterial DNA, lupus mice produce antibodies not only against bacterial DNA but are also cross-reactive to mammalian DNA [38, 39] . Further studies have revealed that anti-dsDNA antibodies specific for bacterial DNA target mainly its base sequential determinants; however, antibodies against selfdsDNA in SLE target its deoxyribose phosphodiester backbone [1, 40] . Mammalian dsDNA is an immunogenic hapten for activating B cells when combined with an appropriate stimulus as the co-stimulatory factor of T helper cells or B cells. For instance, DNA-binding proteins derived from pathogens may enhance the immunogenicity of self-dsDNA, resulting in anti-dsDNA antibody production. Fus1, from the parasitic protozoan Trypanosoma cvuzi and T antigen from polyomavirus, could render mammalian DNA immunogenic in wild-type mice and induce the production of anti-dsDNA antibodies [41, 42] . Antimicrobial peptide LL37 also could bind to dsDNA to activate Toll-like receptor 9 (TLR-9) signalling in pDCs, leading to uncontrolled IFN production that drives autoimmune skin inflammation [43] .
These studies reveal that binding of mammalian DNA with immunogenic polypeptides increases immunogenicity of DNA significantly and could induce anti-dsDNA antibody production in vivo. However, it is also observed that under some circumstances autologous DNA alone is strongly immunogenic without forming complexes with immunogenic peptides. Ultraviolet light (UV), known as the major triggering factor of skin lesion in SLE patients, damages DNA directly and activates the immune response through myeloid dendritic cells [44] . Meanwhile, selfdsDNA damaged by ROS during NETosis is highly immunogenic [34] . The hypomethylated DNA from apoptotic cells is sufficient to induce anti-dsDNA antibodies and lupus-like autoimmune disease, even in SLE nonsusceptible mice [45] . Although how DNA is demethylated and released during the apoptosis process is unclear, the altered modification of DNA during cell death has proved to be crucial for the induction of anti-dsDNA antibody.
The mechanism of how anti-dsDNA antibody is produced in SLE patients remains elusive. Immunogenic self-DNA or the DNA-polypeptide complex may serve as an antigen. Other studies focus upon the breakdown of immune tolerance towards autoantigen by T or B cells. Autoreactive T helper type 0 (Th0) and Th1 cells isolated from SLE patients, which are specific for histone, could induce anti-dsDNA antibody production when co-cultured with autologous B cells in vitro [46] . Meanwhile, autoreactive Th2 could cause a lupus-like symptom with antidsDNA antibody production after being transferred into normal recipient mice [47] . Although it is well accepted that, in healthy individuals, autoreactive B cells exist in vivo without any clinical symptoms, how this special B cell population is generated and maintained is not yet understood fully. Studies show that compared with those in healthy individuals, autoreactive B cells in SLE patients are less anergized [48] . One potential explanation is that genetic and environmental factors break down B cell tolerance, so autoreactive B cells could pass the negative checkpoint unimpeded, therefore participating in GC formation and developing into memory B cells and plasma cells in SLE patients [49] .
IFN-I is produced by innate immune cells in the presence of viral and bacterial nuclear acids, as well as immunogenic self-DNA. IFN-I could promote the functions of autoreactive T and B cells. It is reported that IFN-I significantly lowers the threshold of T and B cell activation [8] , prolongs the survival of activated T cells and promotes memory T cell development [50] . Additionally, IFN-I suppresses regulatory T cell (T reg ) functions and increases Th17 differentiation, which will result in an expansion of autoreactive T cells [51, 52] . With regard to B cells, IFN-I induces the production of B lymphocyte stimulator (BLyS), supporting B cell activation and differentiation through the B cell receptor, as well as facilitating Ig class-switching to generate potentially pathogenic autoantibodies [53, 54] .
Once anti-dsDNA antibody is produced, it binds to its target DNA to form the IC and circulates in blood or, even worse, deposits in tissues. Antigen-presenting cells (APC) such as conventional dendritic cells (DCs), macrophages and pDCs internalize these IC and secret a great deal of proinflammatory cytokines, mainly IFN-I. The antidsDNA antibody plays a critical role in internalization of self-DNA-contained complexes via binding to Fcg surface receptor II (FcgRII) on the cell surface of APC [55, 56] . Moreover, anti-dsDNA antibodies also bind to antigens, expressed in glomerular basement membrane and vascular endothelium, to initiate tissue damage and organ pathogenesis [57, 58] . In conclusion, anti-dsDNA antibodies participate in SLE pathogenesis by forming IC, thereby promoting self-dsDNA cellular uptake by APC to activate IFN-I production through DNA sensors.
DNA sensors and related signal pathways
Foreign DNA, as well as pathogenic self-DNA, is recognized by the immune system via DNA sensors in cytoplasm to activate downstream signal pathways for the immune response. Many DNA sensors have been identified, including TLR-9 [59] , cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase (cGAS) [60] , DNA-dependent activator of IFN-regulatory factors (DAI) [61] , absent in melanoma 2 (AIM2) [62] , gamma-IFNinducible protein 16 (IFI16) [62] , nucleotide-binding domain leucine-rich repeat containing protein family pyrin domain containing 3 (NLRP3) [63] , DEAD/H-box helicase 41 (DDX41) [64] and meiotic recombination 11 (Mre11) [65] . Upon binding of these DNA sensors with their ligands, respectively, signal pathways are activated, which include TLR-9-dependent, stimulator of interferon genes (STING)-dependent and inflammasome-dependent pathways for IFN-I and proinflammatory cytokine production (Fig. 2) . In physiological conditions these intracellular sensors and related pathways are regulated tightly in order to prevent the development of autoimmunity. However, in SLE patients, the presence of excessive self-dsDNA triggers abnormal immune responses and breakdown of selftolerance through these sensors [66] .
TLR-9-dependent signal pathway
TLRs are a major family of pattern recognition receptors in the innate immune system, responsible for activating the immune defence against a wide range of microbial pathogens [67] . In particular, TLR-9 is located in endosomes which recognize bacterial unmethylated CpG-rich DNA and also endogenous nuclear acids, particularly SLEassociated self-DNA [68] . Once TLR-9 binds to intracellular DNA a downstream signal pathway is activated, which utilizes the main adaptor molecule myeloid-differentiation primary response protein-88 (MyD88) and leads to the activation of key transcriptional factors such as the IFN regulatory factor (IRF) and nuclear factor kappa B (NFjB). These two transcriptional factors control the production of IFN-I and proinflammatory cytokines, respectively [69] . TLR-9 serves as the potent sensor to activate pDCs and naive B cells directly (together with B cell receptors). It also activates memory B cells, GC B cells and T cells indirectly through mediating the maturation of APCs in human and mouse [59] .
While the role of TLR-9 in viral infection has been studied extensively, the function of TLR-9 in SLE is still under debate. Some studies find that self-DNA can act as an endogenous antigen that induces autoantibody production through TLR-9. SLE sera or IC-containing self-DNA can activate peripheral blood mononuclear cells (PBMCs), B cells and pDCs isolated from mouse through TLR-9 [59] . Inhibition of TLR-9 signalling in B cells by siRNA reduces the production of anti-dsDNA antibodies and consequently ameliorates the SLE syndrome in the murine model [70] . Moreover, TLR-9-deficient B cells specific for dsDNA are defective in class-switching to pathogenic IgG2a and IgG2b isotypes [71] . In addition, the deletion of Tlr9 in the MRL/ Mp lpr/lpr mouse reduces anti-dsDNA and anti-chromatin antibody production. Consistently, this decrease in antibody titres has been implied in several studies using different TLR-9-deficient lupus-prone mouse models [71] [72] [73] . Studies with human samples have indicated that the TLR9 mRNA level in PBMCs of SLE patients is higher than that in healthy individuals, which is correlated with a higher IFN-a level [74] . The TLR-9 protein level is also elevated consistently in monocytes, T and B cells in SLE patients [75] . Furthermore, the TLR-9 protein level varies during different stages of SLE. Patients with an active phase of SLE have a higher TLR-9 protein level in B cells compared with either patients with inactive SLE or healthy individuals [75] , even though one study reported no correlation between disease activity and TLR-9 protein level [59] . Collectively, these studies provide evidence that the TLR-9 signalling pathway may participate positively in SLE pathogenesis.
Emerging evidence suggests a protective role of TLR-9 in SLE pathogenesis. Although antibody titres have been reduced in TLR-9-deficient lupus mice, as discussed above, more severe lupus symptom-associated manifestations, including glomerulonephritis, immune complex deposition and T cell activation, are observed, accompanied by aberrant TLR-7 activation. Interestingly, the exacerbation of disease in TLR-9-deficient lupus mice can be abrogated totally when Tlr7 is deleted [71, 76] . Further study shows that in steady state, a multi-transmembrane ER resident protein UNC93B1, which is needed for both TLR-7 and TLR-9 signalling, engages TLR-9 preferentially but controls TLR-7 activation [77] . Another study shows that TLR-9 protein can inhibit TLR-7 through direct physical interaction [78] . All these studies may explain the phenotype mentioned in TLR-9-deficient lupus mice. Contrary to the function of TLR-9 in B cells, pDC from SLE patients lacking TLR-9 is less capable of inducing T reg differentiation [79] , which indicates that TLR-9 functions differently in various immune cells of SLE patients. Collectively, these studies suggest that even though autoreactive antibody is a definitive feature of SLE, complex immune pathways are involved in pathogenesis directly or indirectly, and more studies must be conducted to illuminate further the role of TLR-9 in SLE pathogenesis.
STING-dependent pathway
An important role of IFN-I in SLE aetiopathogenesis is proposed when SLE symptoms are observed as a side effect of IFN-a-treated patients with malignant diseases, such as melanoma and renal cell carcinoma [80] . The majority of SLE patients have elevated IFN-I levels in blood and IFN-Istimulated genes (ISGs), a so-called IFN signature, which correlates with stages and severity of SLE [8] . IFN-I is the driving force of pathogenesis which causes the clinical complaints of SLE patients; for instance, fever, rash and leucopenia, which are shared by patients with viral infection [81] .
The STING pathway plays a vital role in IFN-I production upon DNA stimulation. STING is an endoplasmic reticulum resident protein, and expressed broadly in numerous types of cells [82] . Mammalian STING binds to DNA directly but weakly, although it is activated strongly by cyclic dinucleotides (CDNs) generated directly from bacteria such as Listeria monocytogenes [60, 83, 84] . A key DNA interacting protein that expedites STING activity is cGAS which, in the presence of adenosine triphosphate (ATP) and guanosine-5'-triphosphate (GTP), generates non-canonical cyclic dinucleotides (CDNs), a second messenger that binds to and activates STING [60, 85] . Once activated, STING activates TANK-binding kinase 1(TBK1) to phosphorylate downstream transcriptional factors IRF3 and IRF7, which are responsible for IFN-I production [60] . In addition, STING interacts with signal transducer and activator of transcription 6 (STAT-6) and induces sequentially the production of chemokines such as CCL2 and CCL20 independently of IRF3 [86] . STING is also thought to activate the NF-jB pathway through regulating the NFjB inhibitor (IjB), although the mechanism of NF-jB activation downstream of STING remains to be determined [64] . STING-dependent pathways orchestrate the immune response against cytosolic dsDNA, and their effects on the SLE pathogenesis are investigated extensively.
DNase II is crucial for the clearance of self-dsDNA in lysosomes to avoid the immune response. DNase II knock-out mice are embryonically lethal because of uncontrolled inflammation, while the deletion of cGAS in DNase II-deficient mice rescues this lethal phenotype [87] . Three prime repair exonuclease 1 (TREX1), also known as DNase III, is a DNA exonuclease involved in the clearance of cytoplasmic ssDNA and dsDNA. Lostfunction mutations of TREX1 lead to the accumulation of self-DNA and autoimmune disease, such as AicardiGoutières syndrome (AGS) and SLE in humans. TREX1-deficient mice show dramatically reduced survival because of spontaneous inflammatory myocarditis, progressive cardiomyopathy and circulatory failure [88] . Depletion of cGAS, STING, IRF3 or IFN-I receptor in TREX1-deficient mice rescues these mice from autoimmune disorders and mortality [87, 89, 90] , suggesting that the cGAS-STING-IRF3 axis-mediated IFN-I production is responsible for the development of autoimmune disorders in these TREX1-deficient mice. However, in STING-deficient lupus mice, lymphoid hypertrophy, autoantibody production, serum cytokine levels are increased markedly, compared to their STING-sufficient littermates [91] . STING-deficient macrophages fail to express negative regulators of TLR signalling, including cytoplasmic zinc finger protein A20 and suppressor of cytokine signalling1 (SOCS1) and 3 (SOCS3), which leads to hyper-responsiveness to TLR ligands and abnormal production of proinflammatory cytokines [91] . Collectively, these findings reveal that STING has both positive and negative regulatory roles in immune responses.
DAI has been implicated in IFN-I production by activating the STING-dependent pathway in response to poly(-dA:dT) DNA stimulation [61] . Interestingly, DAI expression is induced by activated lymphocytic-derived apoptotic DNA treatment and the level of DAI is increased significantly in SLE patients and in lupus mouse models [92] . Inhibition of DAI signalling with siRNA in lupus mouse models dampens macrophage activation and ameliorates SLE symptoms, including reduced cytokine levels in sera, anti-dsDNA antibody production and IC deposition within the kidney [92] . These findings suggest that the STING-dependent pathway has important functions in the pathogenesis of SLE.
Inflammasome-dependent pathway
The inflammasome is a multi-protein oligomer formed in the myeloid cells as an important mechanism to induce the innate immune response against bacterial and viral infection. Several components of inflammasome, such as AIM2, IFI16 and NLRP3, have been proven to be sensors of self-DNA involved in the pathogenesis of SLE [62] . IC, neutrophil NETs and IFN-I may enhance inflammasome activation in SLE [62] . The activated inflammasome leads to activation of caspase-1, and induces the processing and release of the proinflammatory cytokines interleukin (IL)-1b and IL-18 sequentially from their latent forms. IL-1b is important for the activation of neutrophils, macrophages, DCs and T cells, whereas IL-18 is crucial for IFN-g production by natural killer (NK) cells and T cells [93] . Serum levels of IL-18 are elevated in SLE patients and are correlated with disease severity, autoantibody production and the presence of lupus nephritis. However, the role of IL-1b in SLE is not conclusive [62] .
AIM2 recognizes cytosolic self-dsDNA and pathogenderived dsDNA through its HIN200 domain [94] . AIM2 expression level is correlated strongly with the severity of disease in both SLE patients and the lupus mouse model. Blockage of AIM2 expression ameliorates the SLE syndrome via inhibiting macrophage activation and dampening the inflammatory response in apoptotic DNA-induced lupus mice [95] . Moreover, the expression of AIM2 is gender-dependent and higher in macrophages of male mice or SLE patients, contrary to the gender preference of SLE [96, 97] , which needs to be illuminated further.
The DNA sensor IFI16 belongs to the same ISG family as AIM2, which recognizes DNA through its HIN200 domain [98] . After Kaposi sarcoma-associated herpes virus infection, IFI16 forms an inflammasome complex [99] and recruits STING in cytoplasm, and subsequently activates the TBK1-IRF3 pathway for IFN-I production [98] . Several lines of evidence indicate that IFI16 is an important mediator of inflammation in systemic autoimmune diseases [98] . IFI16 expression is induced by IFN-I, and increased expression levels of IFI16 have been reported in leucocytes isolated from SLE patients [100] .
NLRP3, the central component of inflammasome, has been demonstrated to be related to experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis [101] . NLRP3-deficient mice exhibit reduced Th1 and Th17 responses and impaired IFN-g and IL-17 production [101] . NETs could induce robust activation of the NLRP3 inflammasome in macrophages from SLE patients and lead sequentially to the release of inflammatory cytokines, including IL-18, that further promote NETosis [102] .
Conclusions
Self-dsDNA is restricted in the nucleus or mitochondria, whereby it is compartmentalized away from cytosolic DNA sensors in mammalian cells. Different catalogues of deoxyribonuclease, DNase I, DNase II and DNase III are located in the circulation, lysosome and endoplasmic reticulum, respectively, and are responsible for digesting the unwanted DNA efficiently. In SLE patients, because the clearance of dead cells is defective, self-dsDNA becomes immunogenic after binding to immunogenic polypeptide and/or being modified. Ds-DNA is one of the important triggering factors for SLE. The site and origin of dsDNA, as well as the presence of autoantibodies, are critical for the initiation and pathogenesis of SLE. Autoantibodies are produced by autoreactive B cells with the help of autoreactive T cells, although the mechanism(s) remain elusive. The IC consisting of autoantibodies and self-dsDNA activates intracellular DNA sensors further in immune cells. A strong inflammatory response characterized by robust IFN-I production by APCs (mainly pDCs) is induced via the activation of DNA sensor-dependent signal pathways. The hyperproduction of IFN-I could facilitate DC maturation in turn, and promotes the function of autoreactive T and B cells, resulting in a positive feedback loop involved in the pathogenesis of SLE, suggesting that blocking the DNA sensor-mediated signal pathway would be a potential novel therapeutic strategy for SLE.
